Healthcare -
Biotechnology - NASDAQ - US
$ 6.2432
-1.06 %
$ 22.8 M
Market Cap
-2.38
P/E
1. INTRINSIC VALUE
Balance Sheet
Pulmatrix, Inc.
| Current Assets | 9.92 M |
| Cash & Short-Term Investments | 9.52 M |
| Receivables | 0 |
| Other Current Assets | 399 K |
| Non-Current Assets | 23 K |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 23 K |
| Current Liabilities | 929 K |
| Accounts Payable | 809 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 120 K |
| Non-Current Liabilities | 67 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 67 K |
EFFICIENCY
Earnings Waterfall
Pulmatrix, Inc.
| Revenue | 7.81 M |
| Cost Of Revenue | 435 K |
| Gross Profit | 7.37 M |
| Operating Expenses | 17.6 M |
| Operating Income | -9.76 M |
| Other Expenses | -204 K |
| Net Income | -9.56 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pulmatrix, Inc.
| Net Income | -9.56 M |
| Depreciation & Amortization | 435 K |
| Capital Expenditures | -398 K |
| Stock-Based Compensation | 511 K |
| Change in Working Capital | -4.79 M |
| Others | -1.92 M |
| Free Cash Flow | -11.1 M |
Wall Street Analysts Price Targets
Pulmatrix, Inc.
PULM has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PULM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Pulmatrix, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2024 and provided a corporate update.
prnewswire.com
- 1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pulmatrix, Inc. (NASDAQ:PULM)'s merger with Cullgen Inc. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. If you are a Pulmatrix shareholder, click here to learn more about your rights and options.
accesswire.com
- 6 months ago
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whethe.
businesswire.com
- 6 months ago
PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger
WILMINGTON, DE / ACCESSWIRE / November 14, 2024 / Rigrodsky Law, P.A. is investigating Pulmatrix, Inc. ("Pulmatrix") (NASDAQ CM:PULM) regarding possible breaches of fiduciary duties and other violations of law related to Pulmatrix's agreement to merge with Cullgen Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pulmatrix-inc.
accesswire.com
- 6 months ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pulmatrix , Inc. (NASDAQ: PULM ), relating to the proposed merger with Cullgen, Inc. Under the terms of the agreement, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company.
globenewswire.com
- 6 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
globenewswire.com
- 6 months ago
Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Pulmatrix (Nasdaq: PULM) for possible breaches of fiduciary duty and other violations of law in its transaction with Cullgen. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen.
businesswire.com
- 6 months ago
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Cullgen Inc. is fair to Pulmatrix shareholders. Upon closing of the proposed transaction, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. Halper Sadeh encourages Pulmatrix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or.
businesswire.com
- 6 months ago
Pulmatrix and Cullgen Announce Proposed Merger
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE ™ technology Cullgen and Pulmatrix will host an informational webcast about the proposed merger that will be made available to access at 12:00 pm ET today FRAMINGHAM, Mass. and SAN DIEGO, Calif.
prnewswire.com
- 6 months ago
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 Completed PUR1900 wind down activities Cash runway projected into Q4 2026 FRAMINGHAM, Mass. , Nov. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical assets.
prnewswire.com
- 6 months ago
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRAMINGHAM, Mass. , Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.
prnewswire.com
- 9 months ago
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
prnewswire.com
- 11 months ago
8. Profile
Summary
Pulmatrix, Inc. PULM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 22.8 M
Dividend Yield
0.00%
Description
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Contact
99 Hayden Avenue, Lexington, MA, 02421
https://www.pulmatrix.com
IPO
Date
March 21, 2014
Employees
2
Officers
Mr. Peter Ludlum CMA, MBA
Interim Chief Executive Officer & Interim Chief Financial Officer
Dr. Alexander M. Klibanov Ph.D.
Founder